Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

Sorting through the many opportunities for melanoma therapy.

Herlyn M, Villanueva J.

Pigment Cell Melanoma Res. 2011 Oct;24(5):975-7. doi: 10.1111/j.1755-148X.2011.00906.x. No abstract available.

PMID:
21899726
2.

Optimal treatment selection for patients with metastatic melanoma.

Sullivan RJ.

Oncology (Williston Park). 2015 Feb;29(2):139-41. No abstract available.

3.

Have we won the race in the treatment of advanced melanoma-or are we just learning to walk?

Luke JJ.

Oncology (Williston Park). 2015 Feb;29(2):136, 138-9. No abstract available.

4.

An antibody-drug conjugate targeting the endothelin B receptor for the treatment of melanoma.

Asundi J, Reed C, Arca J, McCutcheon K, Ferrando R, Clark S, Luis E, Tien J, Firestein R, Polakis P.

Clin Cancer Res. 2011 Mar 1;17(5):965-75. doi: 10.1158/1078-0432.CCR-10-2340.

5.

Melanoma response and resistance - taking it to the tumor bank.

Kirkwood JM.

Pigment Cell Melanoma Res. 2011 Oct;24(5):978-9. doi: 10.1111/j.1755-148X.2011.00890.x. No abstract available.

PMID:
21781286
6.

Adjuvant therapy for cutaneous melanoma.

Nathan FE, Mastrangelo MJ.

Semin Oncol. 1995 Dec;22(6):647-61. Review. No abstract available.

PMID:
8539640
7.

Effect of a photoactivated rhodium complex in melanoma.

Kim MR, Morrison H, Mohammed SI.

Anticancer Drugs. 2011 Oct;22(9):896-904. doi: 10.1097/CAD.0b013e32834850a5.

PMID:
21642837
8.

New therapeutic targets in melanoma.

Martí RM, Sorolla A, Yeramian A.

Actas Dermosifiliogr. 2012 Sep;103(7):579-90. Review. English, Spanish.

PMID:
22261672
9.

Triple molecular target approach to selective melanoma cytotoxicity.

Skibo EB, Jamil A, Austin B, Hansen D, Ghodousi A.

Org Biomol Chem. 2010 Apr 7;8(7):1577-87. doi: 10.1039/b920260a.

PMID:
20237668
10.

[To outwit melanoma with its own tricks].

Bischoff A.

MMW Fortschr Med. 2003 Apr 10;145(15):4-6, 8, 10. Review. German. No abstract available.

PMID:
15104255
11.

Novel therapeutic agents under investigation for malignant melanoma.

Pavlick AC, Adams S, Fink MA, Bailes A.

Expert Opin Investig Drugs. 2003 Sep;12(9):1545-58. Review.

PMID:
12943498
12.

Combination of targeted therapy and immunotherapy in melanoma.

Blank CU, Hooijkaas AI, Haanen JB, Schumacher TN.

Cancer Immunol Immunother. 2011 Oct;60(10):1359-71. doi: 10.1007/s00262-011-1079-2. Review.

PMID:
21847631
13.

CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer.

Wang X, Osada T, Wang Y, Yu L, Sakakura K, Katayama A, McCarthy JB, Brufsky A, Chivukula M, Khoury T, Hsu DS, Barry WT, Lyerly HK, Clay TM, Ferrone S.

J Natl Cancer Inst. 2010 Oct 6;102(19):1496-512. doi: 10.1093/jnci/djq343.

14.

New molecular targets in melanoma.

Flaherty KT.

Curr Opin Oncol. 2004 Mar;16(2):150-4. Review.

PMID:
15075908
15.

Molecular markers of response to treatment for melanoma.

Sznol M.

Cancer J. 2011 Mar-Apr;17(2):127-33. doi: 10.1097/PPO.0b013e318212dd5a. Review.

PMID:
21427556
16.
17.

5-AZA-2'-deoxycytidine in cancer immunotherapy: a mouse to man story.

Coral S, Sigalotti L, Covre A, Nicolay HJ, Natali PG, Maio M.

Cancer Res. 2007 Mar 15;67(6):2900-1; author reply 2901-2. No abstract available.

18.

Molecular targeted therapy for patients with melanoma: the promise of MAPK pathway inhibition and beyond.

Sullivan RJ, Atkins MB.

Expert Opin Investig Drugs. 2010 Oct;19(10):1205-16. doi: 10.1517/13543784.2010.504709. Review.

PMID:
20687784
19.

Inhibition of c-Met with the specific small molecule tyrosine kinase inhibitor SU11274 decreases growth and metastasis formation of experimental human melanoma.

Kenessey I, Keszthelyi M, Krámer Z, Berta J, Adám A, Dobos J, Mildner M, Flachner B, Cseh S, Barna G, Szokol B, Orfi L, Kéri G, Döme B, Klepetko W, Tímár J, Tóvári J.

Curr Cancer Drug Targets. 2010 May;10(3):332-42.

PMID:
20370683
20.

Chemoimmunotherapy increases the lymphocyte reactivity of melanoma patients.

Berkelhammer J, Mastrangelo MJ, Bellet RE, Berd D, Prehn RT.

Eur J Cancer. 1979 Feb;15(2):197-204. No abstract available.

PMID:
436896

Supplemental Content

Support Center